Enhanced Enterococcus Gallinarum Flagellin Polypeptides for Improved Immunogenicity and Therapeutic Efficacy

The present inventive concept relates to improved flagellin polypeptides from Enterococcus gallinarum, enhancing their immunogenicity and therapeutic efficacy through modifications, optimized production, and targeted delivery.

The original patent disclosed pharmaceutical compositions comprising isolated Enterococcus flagellin polypeptides, but these compositions may have limitations in terms of immunogenicity and therapeutic efficacy. The present inventive concept addresses these limitations by providing enhanced flagellin polypeptides with improved exposure to TLR5 receptors, optimized production, and targeted delivery.

The new claims describe methods for enhancing the immunogenicity of Enterococcus flagellin polypeptides by modifying the D0 domain to increase its exposure to TLR5 receptors. Additionally, the claims cover systems for delivering the polypeptide to target sites using nanoparticles, co-administration with adjuvants, and optimized production methods through bacterial host engineering. These enhancements improve the immune response and therapeutic efficacy of the flagellin polypeptides.

The new claims provide a non-obvious improvement over the original patent by introducing modifications that increase the exposure of the D0 domain to TLR5 receptors, using nanoparticles for targeted delivery, and optimizing production through bacterial host engineering. These enhancements result in improved immunogenicity and therapeutic efficacy, making the inventive concept novel and non-obvious.

Alternative embodiments of the inventive concept could include different types of nanoparticles, adjuvants, or bacterial hosts. Variations of the modified D0 domain could also be explored to further optimize the immunogenicity of the flagellin polypeptides.

The enhanced Enterococcus gallinarum flagellin polypeptides have potential commercial applications in the development of vaccines and immunotherapies for various diseases. The target market includes pharmaceutical and biotechnology companies focused on infectious disease treatments and cancer therapies.